TG Therapeutics

What TG Therapeutics does

TG Therapeutics, Inc. (NASDAQ: TGTX) is a commercial-stage biopharmaceutical company headquartered in Morrisville, North Carolina, focused on developing therapeutics for B-cell mediated diseases, with current commercial emphasis on relapsing forms of multiple sclerosis. The company's lead and only marketed product is BRIUMVI (ublituximab-xiiy), an FDA-approved (January 2023) glycoengineered anti-CD20 monoclonal antibody that enhances antibody-dependent cellular cytotoxicity (ADCC) via removal of fucose sugar residues. BRIUMVI is administered as an intravenous infusion every six months after initial dosing and generated $594.1 million in US net product revenue in 2025 (92% YoY growth), with over 25,000 patients treated globally.

The company's pipeline leverages two distinct technology platforms: the glycoengineered anti-CD20 antibody platform (currently marketed as IV BRIUMVI, plus a subcutaneous formulation in Phase 3 with self-administration potential) and an allogeneic CAR-T platform centered on azercabtagene zapreleucel (azer-cel), a CD19-directed off-the-shelf cell therapy in Phase 1 for progressive MS and other autoimmune conditions, licensed from Precision BioSciences. Clinical differentiation is supported by a 56.7% reduction in annualized relapse rate versus teriflunomide, a 0.020 annualized relapse rate at Year 5, and 92% of patients progression-free at Year 5.

TG Therapeutics monetizes BRIUMVI through a direct US sales force targeting neurologists and MS treatment centers, with prescription pricing negotiated bilaterally through insurance carriers, PBMs, and healthcare systems rather than publicly listed. International commercialization is executed via a partnership with Neuraxpharm covering the EU, UK, Switzerland, Australia, Kuwait, and UAE. Secondary revenue derives from licensing and milestone payments tied to the azer-cel program. The company has reached profitability with $19.8M in Q1 2026 net income and EPS of $2.87, supported by a $750M senior secured credit facility (expandable to $1B) from Blue Owl Capital secured in March 2026 that provides non-dilutive growth capital alongside an expanded $300M share repurchase authorization.

Name

TG Therapeutics

Legal name

TG Therapeutics, Inc.

Website

https://tgtherapeutics.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

501–1,000 employees

Short description

TG Therapeutics is a commercial-stage biopharmaceutical company that develops and markets BRIUMVI (ublituximab-xiiy), a glycoengineered anti-CD20 monoclonal antibody FDA-approved for relapsing multiple sclerosis, with a pipeline spanning subcutaneous formulations and allogeneic CAR-T therapies for B-cell mediated diseases.

Ownership category

akta.pro rank

Product category

Multiple Sclerosis Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

Keywords

• Multiple sclerosis therapeutics
• Monoclonal antibody therapy
• Biopharmaceutical products
• CAR-T cell therapy
• Autoimmune disease drugs

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. BRIUMVI Product Sales: Commercial revenue from sales of FDA-approved BRIUMVI (ublituximab-xiiy) for relapsing multiple sclerosis. Revenue has grown from $89 million in 2023 to $594 million in 2025 (U.S. net product revenue), with 2026 guidance of $885-900 million.
2. Licensing and Milestone Payments: Revenue from licensing agreements including milestone payments from Precision BioSciences for azer-cel development progress ($7.5 million milestone received in March 2026), with up to $288 million in additional milestones available under the agreement.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

TG Therapeutics develops and commercializes therapeutics for B-cell mediated diseases, with its flagship commercial product BRIUMVI (ublituximab-xiiy) — a glycoengineered anti-CD20 monoclonal antibody FDA-approved for relapsing forms of multiple sclerosis in adults. The pipeline expands on this platform with a subcutaneous ublituximab formulation in Phase 3 (designed for at-home self-administration) and azercabtagene zapreleucel (azer-cel), an investigational CD19-directed allogeneic CAR-T cell therapy for progressive MS and other autoimmune conditions.

Product overview

TG Therapeutics is a commercial-stage biopharmaceutical company focused on B-cell diseases, primarily multiple sclerosis. The company markets BRIUMVI (ublituximab-xiiy), an FDA-approved glycoengineered anti-CD20 monoclonal antibody delivered via IV infusion for relapsing forms of MS. The pipeline includes a subcutaneous formulation of ublituximab in Phase 3 development for at-home self-administration, and azercabtagene zapreleucel (azer-cel), a CD19-directed allogeneic CAR-T cell therapy in Phase 1 for progressive MS and other autoimmune conditions.

Differentiator

Problem solved

Functional benefit

Brands

• BRIUMVI: FDA-approved brand name for ublituximab-xiiy, used for treatment of relapsing forms of multiple sclerosis

Products and services

• BRIUMVI (ublituximab-xiiy) FDA-approved glycoengineered anti-CD20 monoclonal antibody for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Administered via intravenous infusion (typically every six months after initial dosing). Sold to neurologists and MS treatment centers across the United States and through Neuraxpharm internationally.
• Subcutaneous Ublituximab Subcutaneous formulation of ublituximab being evaluated in Phase 3 clinical trials for adults with relapsing multiple sclerosis. Designed for self-administration via subcutaneous injection (every 8 or 12 weeks), offering an at-home treatment option as an alternative to IV infusion.
• Azercabtagene zapreleucel (azer-cel) CD19-directed allogeneic CAR-T cell therapy being developed for B-cell mediated autoimmune conditions including progressive multiple sclerosis. Uses healthy donor T cells modified with proprietary gene-editing technology to express CD19-directed CAR while minimizing graft-versus-host disease (GvHD) risk, enabling off-the-shelf availability.

Quantifiable outcome

• 56.7% reduction in annualized relapse rate compared to teriflunomide in treatment-naive patients
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Precision BioSciencescoreStrategic or Co-development Partner · 1 January 2024TG Therapeutics holds exclusive worldwide rights to develop and commercialize azer-cel (azercabtagene zapreleucel) in autoimmune diseases through licensing agreement with Precision BioSciences. TG paid $7.5 million milestone for Phase 1 trial progress in progressive MS, with up to $288 million in additional milestones plus royalties available.
• NeuraxpharmcoreChannel Partner/ Reseller/ Distributor · 1 January 2023Collaboration with Neuraxpharm for European and international commercialization of BRIUMVI. The partnership expanded commercialization across European Union, United Kingdom, Switzerland, Australia, Kuwait, and United Arab Emirates following initial European regulatory approvals.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Sanofi: Markets teriflunomide (Aubagio), the active comparator used in BRIUMVI's pivotal ULTIMATE I & II trials. Competes in the same MS treatment paradigm as TG Therapeutics.
• Genentech (Roche): Maker of Ocrevus (ocrelizumab), the leading anti-CD20 monoclonal antibody for relapsing MS and the primary head-to-head competitor to BRIUMVI. Direct product overlap, same patient population, similar mechanism of action.
• Novartis: Markets Kesimpta (ofatumumab), a subcutaneous anti-CD20 monoclonal antibody for relapsing MS. Competes head-to-head with BRIUMVI on anti-CD20 mechanism with the convenience advantage of self-administered subcutaneous injection.
• EMD Serono (Merck KGaA): Markets Mavenclad (cladribine) for relapsing MS, an oral disease-modifying therapy competing for the same high-efficacy patient segment as BRIUMVI. Direct commercial overlap in the relapsing MS market.
• Bristol Myers Squibb: Markets Zeposia (ozanimod) for relapsing MS, an oral S1P receptor modulator. Direct competitor targeting the same relapsing MS patient population with a differentiated oral mechanism.

Emerging players

• Allogene Therapeutics: Allogeneic CAR-T developer with pipeline programs targeting autoimmune diseases. Competes in the same allogeneic CAR-T autoimmune space as TG's azer-cel.
• CRISPR Therapeutics: Developing allogeneic CAR-T cell therapies for autoimmune diseases, directly overlapping with TG's azer-cel program in progressive MS and broader B-cell mediated autoimmune indications.
• Cabaletta Bio: Clinical-stage biotech developing CAR-T cell therapies (e.g., CABA-201) for autoimmune diseases including lupus and other B-cell mediated conditions. Overlapping target indications with TG's azer-cel program.

Broad incumbents

• Biogen: Long-established MS franchise with TYSABRI, AVONEX, PLEGRIDY, and VUMERITY serving the same relapsing MS patient population as BRIUMVI. Major incumbent in MS treatment with broad portfolio and deep neurologist relationships.

Others

• Precision BioSciences: Licensor of azer-cel technology to TG Therapeutics. Partner with material economic interest in azer-cel milestones (up to $288M plus royalties) and recent equity investment from TG.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/TGTherapeutics
• LinkedInlinkedin.com/company/tg-therapeutics
• Facebookfacebook.com/344107792338021

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TG Therapeutics